IP Library Granted Patent US 8,124,100
Granted Patent B2
US 8,124,100 · App. 12/425,135 · Granted Feb 28, 2012

Inactivated nodavirus vaccine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,100
App. No.
12/425,135
Granted
Feb 28, 2012
Kind
B2
Abstract

A vaccine against nodavirus infection in fish can be produced by inactivating the virus using an aziridine compound. This vaccine can be used to prevent Viral Nervous Necrosis (VNN) in a variety of fish species.

Claims (11)

1. An inactivated piscine viral nervous necrosis virus (NNV) strain Mt/01/Sba deposited with the ECACC under Accession No. 03060401, wherein the inactivated piscine viral nervous necrosis virus when administered to fish, is capable of providing a relative percent survival (RPS) of at least 50% after challenge with a non-inactivated NNV strain of Mt/01/Sba, and wherein the inactivated piscine viral nervous necrosis virus is inactivated with binary ethyleneimine.

2. A vaccine composition comprising:

an inactivated piscine viral nervous necrosis virus (NNV) strain Mt/01/Sba deposited with ECACC under Accession No. 03060401; and

a pharmaceutically acceptable carrier,

wherein the inactivated piscine viral nervous necrosis virus is inactivated with binary ethyleneimine.

3. The vaccine composition of claim 2 , wherein the vaccine is capable of providing a relative percent survival (RPS) of at least 77% in a fish population vaccinated with the vaccine subsequent to challenge with a non-inactivated NNV strain of Mt/01/Sba.

4. The vaccine composition of claim 3 , wherein the RPS is at least 91.55%.

5. The vaccine composition of claim 2 , further comprising about 10 2 to about 10 9 TCID 50 of the inactivated nodavirus per unit dose.

6. The inactivated piscine viral nervous necrosis virus of claim 1 , wherein when administered to fish, is capable of providing a relative percent survival (RPS) of at least 77% after challenge with a non-inactivated NNV strain of Mt/01/Sba.

7. The inactivated piscine viral nervous necrosis virus of claim 1 , wherein when administered to fish, is capable of providing a relative percent survival (RPS) of at least 91% after challenge with a non-inactivated NNV strain of Mt/01/Sba.

8. The vaccine composition of claim 2 , further comprising an adjuvant.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2024
From: NOVARTIS ANIMAL HEALTH US, INC.
To: NOVARTIS AG
Reel/Frame 067136/0113 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2024
From: NOVARTIS AG
To: ELANCO TIERGESUNDHEIT AG (F/K/A NOVARTIS TIERGESUNDHEIT AG),
Reel/Frame 067136/0142 →
CHANGE OF NAME Recorded Aug 25, 2017
From: NOVARTIS TIERGESUNDHEIT AG
To: ELANCO TIERGESUNDHEIT AG
Reel/Frame 043402/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2015
From: NOVARTIS AG
To: NOVARTIS TIERGESUNDHEIT AG
Reel/Frame 035021/0975 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2011
From: NOVARTIS ANIMAL HEALTH US, INC.
To: NOVARTIS AG
Reel/Frame 025600/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2010
From: DOS SANTOS, NUNO; IRELAND, JACQUELINE; BARNES, ANDREW CARTNER; HORNE, MICHAEL
To: NOVARTIS ANIMAL HEALTH US, INC.
Reel/Frame 024886/0269 →